Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

ALNY has been the topic of a number of other reports. ValuEngine raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Piper Jaffray Companies set a $116.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 24th. Credit Suisse Group reissued a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Needham & Company LLC boosted their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the stock an “equal weight” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $79.79.

Shares of Alnylam Pharmaceuticals (ALNY) opened at 82.44 on Friday. The firm’s market cap is $7.11 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The firm has a 50-day moving average of $80.45 and a 200-day moving average of $59.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The business’s revenue was up 160.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.21) EPS. On average, analysts expect that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Upgraded to “Strong-Buy” at BidaskClub” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/alnylam-pharmaceuticals-inc-alny-upgraded-to-strong-buy-at-bidaskclub.html.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at $1,597,275. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. First Manhattan Co. acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $135,000. CIBC Asset Management Inc acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $221,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $148,000. Capstone Asset Management Co. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $232,000. Finally, Hemenway Trust Co LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $235,000. Institutional investors and hedge funds own 88.96% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.